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25 and the SF-36. Psychometric analyses of baseline data exam-
ined internal consistency (Cronbach’s alpha), criterion validity
(Spearman correlations), and discriminant validity of the VFQ-
25. RESULTS: The 684 enrolled patients were primarily Cau-
casian (77.8%) and male (63.3%), with a mean age of 59.3
years. Cronbach’s alphas for VFQ-25 scales indicated good inter-
nal consistency, ranging from 0.72 to 0.93 for all subscales
except two 2-item subscales, which had alphas of 0.68 (ocular
pain) and 0.64 (social functioning). The VFQ-25 demonstrated
convergent validity through statistically signiﬁcant correlations
with SF-36 subscales. For example, correlations of the VFQ-25
role difﬁculties subscale with the eight SF-36 subscales ranged
from 0.25 to 0.35 (all p < 0.0001). VFQ-25 subscales signiﬁcant
discriminated among groups of patients differing in ETDRS
visual acuity scores (e.g., total VFQ-25 score = 79.1 for patients
with ETDRS score of 48–78 letters; 83.0 for patients with 79–84
letters; 89.0 for patients with 85–100 letters). CONCLUSION:
The VFQ-25 demonstrated adequate internal consistency relia-
bility, criterion validity, and discriminant validity. Results
support the use of this instrument among patients with diabetic
retinopathy.
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OBJECTIVES: Intensive treatment to achieve targeted glycemic
index(HbA1c <7% and FBG <140 mg%) with the help of early
initiation of basal insulin secretion in addition to oral hypo-
glycemic agents has been proposed for type 2 diabetes mellitus.
Insulin glargine has been reported to be as efﬁcacious as NPH
insulin along with oral hypoglycemic agents in type 2 diabetes
mellitus. However, its impact on quality of life has not been eval-
uated. METHODS: Forty patients of type 2 diabetes mellitus on
two or more oral hypoglycemic agents for more than three
months and unable to achieve targeted glycemic index were
enrolled and randomized in a open label comparative trial into
two groups, 20 patient each, taking either insulin glargine or
NPH insulin in combination to previous treatment. The end
points evaluated were glycemic index, hypoglycemic episodes
impact on treatment satisfaction, well being and quality of life.
RESULTS: Both the treatment groups equally achieved eug-
lycemic levels. The mean decrease in HbA1c levels in both groups
was the same but more number of patients (15 vs. 10) were able
to achieve fair to good glycemic control in Insulin glargine group.
Total episodes of hypoglycemia were 50% lesser in insulin
glargine group (13 vs. 26) with no severe and lesser nocturnal
episodes. Quality of life parameters improved in both groups but
were signiﬁcantly higher in insulin glargine group (treatment sat-
isfaction: 43.75 ± 2.05 vs. 34.44 ± 1.68; General well being: 27.1
± 2.37 vs. 16.75 ± 1.58; Total satisfaction: 35.50 ± 2.25 vs. 23.81
± 1.92). Higher number of people had overall good to excellent
rating of quality of life (18 vs. 10). CONCLUSION: Achieve-
ment of target glycemic control was similar in both insulin reg-
imens however; patients on insulin glargine had signiﬁcantly
lesser number of hypoglycemic episodes and far better treatment
satisfaction, Sense of well being and quality of life.
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OBJECTIVES: Hypoglycemia presents a challenge for patients
using insulin. The fear and anxiety related to hypoglycemic
episodes may inhibit intensiﬁed insulin treatment and cause
patients to reduce driving, limit social activities and eat snacks.
However, published estimates of health-related quality of life
values (utilities) for hypoglycemia have been based on database
studies and not directly measured in interviews. Our objective
was to elicit societal and patient utilities in Canada for ﬁve 
health states including: diabetes, rare (quarterly), intermittent
(monthly), frequent (weekly), and nocturnal hypoglycemia
episodes. METHODS: The health state descriptions were based
on the validated Hypoglycemia Fear Survey and the opinions of
four experts. Time trade-off (TTO) interviews were used to elicit
utilities from 79 non-diabetic and 50 diabetic respondents in
Canada. The TTO method estimates utilities between 0 and 1,
where 1 expresses full health and 0 represents dead. Interview-
ers used a TTO board that allowed respondents to trade between
zero and 30 years of perfect health against 30 years in each
health state. RESULTS: The diabetes health state was estimated
at 0.92 (SD 0.13) and 0.88 (SD 0.13) by diabetics and non-dia-
betics, respectively. The disutility was greater with increasing
hypoglycemia: rare episodes ranged from −0.01 to −0.03 in the
two groups; intermittent −0.05 to −0.11; frequent −0.17 to 
−0.22; and nocturnal −0.12 to −0.17. In both groups, the disu-
tility of nocturnal hypoglycemia was intermediate between inter-
mittent and frequent rates hypoglycemia. CONCLUSION: Rare
hypoglycemia episodes occurring only a few times a year, was
rated as having only a minimal impact, whereas frequent
episodes and nocturnal hypoglycemia had substantial impacts.
This study is the ﬁrst to directly estimate utilities for hypo-
glycemia, incorporating appropriately developed health states,
using direct elicitation techniques, and including diabetic and
non-diabetic respondents.
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OBJECTIVES: This study reports differences in utility scores
obtained using the U.S. and U.K. valuations of the EQ-5D in a
cross-sectional study among patients with type 2 diabetes melli-
tus (T2DM). METHODS: Patients with T2DM at the outpatient
clinics of a university hospital completed the EQ-5D. Health
state preference scores were obtained using both the US and UK
valuation systems of the EQ-5D, and matched with retrospective
data including A1C, co-morbidities, diabetes-related complica-
tions, and BMI from electronic records and with self-report of
insulin use and depressive symptoms (using the Center for Epi-
demiologic Studies—Depression). Paired sample t-tests assessed
overall differences in US and UK scores. Using EQ-5D scores as
the dependent variable, OLS regressions assessed the signiﬁcance
of diabetes-related complications and co-morbidities as predic-
tors (dichotomized) individually; these were also preformed
using US-UK difference scores as the dependent variable.
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RESULTS: Usable response rate was 37% (n = 363). Mean A1C
was 7.2 (SD 1.4), mean diabetes duration was 10.2 (SD 9.1)
years, 62.1% were obese (BMI >30), and about 42% used
insulin. Mean (SD) and range of EQ-5D index scores were:
0.71(0.21), −0.04 to 1.00 for the US; 0.60(0.32), −0.48 to 1.00
for the UK. Spearman’s correlation between US and UK scores
was 0.998 (p < 0.001). A paired samples t-test indicated that the
US valuations were signiﬁcantly higher (p < 0.001) with the mean
difference being 0.11(0.11). In individual OLS regressions, those
with neurological complications, ischemic heart disease, obesity
or depressive symptoms had signiﬁcantly higher EQ-5D US
scores as well as UK scores. These conditions also signiﬁcantly
predicted greater differences between US and UK scores. CON-
CLUSION: Although well correlated, the U.S population means
were signiﬁcantly higher than UK population means, and this
difference was seen across clinically relevant categories in
T2DM. The preference scoring system employed may therefore
inﬂuence results of research conducted using the EQ-5D instru-
ment to measure preferences.
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OBJECTIVES: Regulatory agencies demand QALYs as evidence
of effectiveness in economic evaluation. This is a challenge for
clinical studies in which outcomes are measured using condition-
speciﬁc instruments that lack the required measurement proper-
ties. This study aims to provide a model for deriving EQ-5D
utilities directly from the QoL-AGHDA. These estimates were
used to calculate QALY deﬁcit and treatment effects in adults
with GHD in relation to the general population values.
METHODS: A UK postal survey captured QoL-AGHDA (a con-
dition-speciﬁc measure for patients with GHD) and EQ-5D
responses from a broadly representative sample of the general
population (n = 921). These data were used to construct two-
step regression model (R2 = 0.42). In the ﬁrst, TTO-weighted ED-
5Dindex was the dependent variable and yes/no responses to all 25
QoL-AGHDA items were coded as dichotomous dummy vari-
ables (xi). In the second step utilities were computed as follows:
QoL-AGHDAutility = b0 + c*age + Σbi*xi + ei. QoL-AGHDAutility
at yearly visits for 894 UK patients followed in the KIMS data-
base was computed using the same regression model. Subse-
quently the mean QALY over time were compared to baseline
values and assessed in relation to the cross-sectional age/gender
population values. RESULTS: Health related quality of life mea-
sured by QoL-AGHDAutility in patients prior to GH replacement
differed signiﬁcantly from age/gender-matched values in the
general population (0.67 vs. 0.85, p < 0.0001). After the ﬁrst
year of treatment the deﬁcit was reduced to −0.07. Despite a dra-
matic improvement during the ﬁrst year of treatment, patients’
health status remained signiﬁcantly different from general pop-
ulation reference values (p < 0.001) over the course of their treat-
ment. Nevertheless, a mean undiscounted gain from baseline of
0.32 QALYs was seen in the treated patients, corresponding to
0.08 QALYs per year. CONCLUSION: Estimates of treatment
beneﬁt for use in economic evaluation can be successfully derived
from condition-speciﬁc measures.
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OBJECTIVES: To evaluate the impact of Generalized Anxiety
Disorder (GAD) on diagnosed comorbidities, medication use and
treatment costs. METHODS: Claims were drawn from Phar-
Metrics Integrated Outcomes Database for 12-month prior and
post the ﬁrst GAD (ICD9-CM: 30002) diagnosis between
Janaury 2003 and June 2004 (the diagnosis date as the index
date). No GAD diagnosis 12-month prior the index date, 24-
month continuous insurance eligibility and aged 18–64 were
required. Changes in diagnoses of comorbidities, medication use
patterns, and treatment costs between the year before and after
the index date were examined. Comparison among subgroups of
GAD patients with comorbid depression and pain was also inves-
tigated. Wilcoxon Signed Rank test and McNemar’s test were
used to examine pre-post differences for continuous and cate-
gorical variables, respectively. RESULTS: A total of 240,041
patients were included in this study. The mean age was 41.7 years
old and 67% were female. After diagnosis of GAD, a signiﬁ-
cantly higher percent of patients were diagnosed with depression
(44.4% vs. 30.9%, p < 0.001), dyslipidemia (24.0% vs.19.9%,
p < 0.001), and diabetes (6.1% vs. 5.3%, p < 0.001) than before
GAD diagnosis. The use of antidepressants increased from
42.3% to 56.8% (p < 0.001). Compared to the year prior to
GAD diagnosis, total annual costs increased by $2034 (p <
0.001) driven mainly by increases of inpatient and outpatient
costs ($285 and $773, p < 0.001, GAD only and increased
merely $306 for GAD patients with depression while GAD
patients with pain and those with both pain and depression
increased by $2253 and $4665 (both p < 0.001), respectively.
CONCLUSION: Diagnosis of GAD had signiﬁcant impact on
comorbidities, medication use and treatment costs. Furthermore,
comorbid pain and depression had substantial extra burden on
GAD patients as compared with those had GAD only. Recog-
nizing these comorbidities is important in the treatment of
patients with GAD.
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